Bylieve Study Results: Alpelisib And Endocrine Therapy In Patients With Pik3Ca-Mutated/Hr+/Her2-...

BYLieve study results: Alpelisib and endocrine therapy in patients with PIK3CA-mutated/HR+/HER2-...

BYLieve Study Cohort A: alpelisib + ET in PIK3CA-mutant, HR+, HER2-, advanced breast cancer

BYLieve additional cohort: update on the trial of alpelisib in advanced breast cancer from ESMO

Adding alpelisib for HR+/HER2- advanced breast cancer in SOLAR-1: adverse event impacts

ASCO: Alpelisib Plus Fulvestrant for PIK3CA-Mutated Breast Cancer After Failure of CDK4/6 Inhibitors

Sequencing endocrine treatment in metastatic luminal breast cancer and alpelisib for treatment o...

OS results from SOLAR-1 trial of alpelisib reported | Fabrice André

Medicine Matters oncology

Results of the BELLE-3 study of buparlisib for advanced breast cancer

Alpelisib in the Management of PIK3CA-Mutated Breast Cancer

PIKing The Right Strategy for patients with HR+/HER2-, PIK3CA mutation

Cancer education made simple # Chandrakanth MV

Alpelisib: A Promising Breakthrough in Precision Medicine for Breast Cancer

Alpelisib plus fulvestrant for advanced breast cancer: Subgroup analyses from the phase III SOLA...

Common breast cancer drug alpelisib may have an alarming side effect, finds study

Medical Dialogues

PI3K Inhibitors in HR+ Metastatic Breast Cancer

Update on PIK3CA Inhibitor (Alpelisib) in Lymphatic Anomalies

Lymphangiomatosis & Gorham's Disease Alliance (LGDA)

MONARCH 2: abemaciclib added to fulvestrant shows OS benefit in HR+/HER2- advanced breast cancer

Exploring Abemaciclib for the Treatment of Brain Metastases in HR+/HER2- Breast Cancer

Targeted Oncology

Dr. Jhaveri on Results of Taselisib in PIK3CA-Mutated Metastatic Solid Tumors

MonarchE 4-year: abemaciclib + endocrine therapy for HR+, HER2-, node-positive, high-risk early BC

Palbociclib, pembrolizumab, and endocrine therapy in HR+/HER2- breast cancer